Bicycle Therapeutics plc
NASDAQ:BCYCBiotechnology
-$0.06 today
- Market cap
- $217.99M
- Beta
- 1.54
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$3.14
Volume 0.57M
Average 0.49M
BCYC Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Bicycle Therapeutics plcNASDAQ: BCYC
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables falls 11.8% from a year ago
Net receivables stood at $40.92M at the end of Q1 FY2026, down 11.8% from a year earlier and up 15.0% from the prior quarter. Over 3 fiscal years it compounded at +18.8% a year.
Context
- Net receivables amounted to 6.3% of total assets at the end of Q1 FY2026, up 1.0 pp from a year earlier.
- Net receivables increased in 2 of the last 3 fiscal years.
What to watch
Whether net receivables keeps falling in the next quarterly balance sheet after a -11.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 35.59M USD
- Year-over-year change
- -0.2%
- 4-year CAGR
- +31.5%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 35.59M | -0.2% |
| FY2024 | 2024-12-31 | 35.65M | +48.3% |
| FY2023 | 2023-12-31 | 24.04M | +13.4% |
| FY2022 | 2022-12-31 | 21.21M | +78.1% |
| FY2021 | 2021-12-31 | 11.91M | — |
Net Receivables vs competitors
How BCYC compares with its peers on the latest reported figures
- BCYC's Mar 2026 net receivables of $40.92M is the highest of the 10 companies compared; the peer median is $1.78M.
- Its year-over-year change of -11.8% is the 3rd highest of 5, against a peer median of -16.2%.
- Net receivables amounts to 6.3% of total assets for BCYC, versus a peer median of 0.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $40.92M | -11.8% | +18.8% | 6.3% | |
| Mar 2026 | $37.51M | +566.5% | -46.9% | 13.1% | |
| Mar 2026 | $31.05M | -2.3% | -26.4% | 10.7% | |
| Mar 2026 | $11.78M | -75.2% | +339.9% | 4.4% | |
| Dec 2025 | $11.3M | — | — | 3.4% | |
| Mar 2026 | $1.78M | -30.1% | -0.3% | 0.5% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $0 | — | — | 0.0% |
| Peer median (excluding BCYC) | $1.78M | -16.2% | -13.4% | 0.5% | |
Competitors are the stored peer set for BCYC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 438.68M | 339.15M | 526.42M | 879.52M | 628.11M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 11.91M | 21.21M | 24.04M | 35.65M | 35.59M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 7.97M | 9.02M | 11.41M | 13.43M | (35.59M) |
| Total Current Assets | 458.56M | 369.38M | 561.87M | 928.61M | 628.11M |
| Property, Plant & Equipment (Net) | 17.79M | 32.77M | 27.68M | 17.19M | 21.91M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 547K | 547K | 58K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.45M | 8.46M | 5.24M | 10.53M | 12.75M |
| Total Non-current Assets | 21.24M | 41.23M | 33.48M | 28.26M | 34.71M |
| Total Assets | 479.79M | 410.61M | 595.34M | 956.87M | 717.6M |
| Account Payables | 2.72M | 6.47M | 13.05M | 15.79M | 9.67M |
| Short-term Debt | 0 | 0 | 4.88M | 0 | 2.76M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 19.27M | 20.42M | 24.98M | 10.19M | 2.96M |
| Other Current Liabilities | 7M | 13.4M | 13.24M | 16.57M | 17.14M |
| Total Current Liabilities | 36.24M | 53.34M | 69.54M | 67.23M | 56.98M |
| Long-term Debt | 29.87M | 30.32M | 30.7M | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 52.07M | 41.46M | 110.22M | 91.47M | 35.51M |
| Other Non-current Liabilities | 3.28M | 3.83M | 4.58M | 1.12M | 363K |
| Total Non-current Liabilities | 97.3M | 86.48M | 154.88M | 96.58M | 50.64M |
| Total Liabilities | 133.54M | 139.83M | 224.41M | 163.81M | 107.62M |
| Common Stock | 384K | 387K | 550K | 890K | 894K |
| Retained Earnings | (218.38M) | (331.1M) | (511.76M) | (680.79M) | (899.75M) |
| Accumulated OCI | (3.39M) | 387K | (1.3M) | 119K | (3.51M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 346.25M | 270.78M | 370.93M | 793.06M | 609.98M |
| Total Debt | 44.34M | 44.33M | 44.96M | 9.49M | 17.52M |
| Net Debt | (394.34M) | (294.83M) | (481.47M) | (870.03M) | (610.59M) |
Bicycle Therapeutics plc
NASDAQ:BCYC
Intrinsic Alpha fair value
Locked
Current Price
$3.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.